Cargando…
Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn’s Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature
Use of ustekinumab in Crohn’s disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn’s disease, who developed an anaplastic large cell T cell lymphoma during treatment with usteki...
Autores principales: | Smeets, Fabiënne G M, Liedorp, Paulien R, van der Poel, Marjolein, Miclea, Razvan L, Masclee, Ad A M, Pierik, Marieke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142401/ https://www.ncbi.nlm.nih.gov/pubmed/31116402 http://dx.doi.org/10.1093/ecco-jcc/jjz084 |
Ejemplares similares
-
Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohn’s disease
por: Xu, Pan, et al.
Publicado: (2021) -
Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016) -
Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019) -
Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
por: Xiao, Teresa L., et al.
Publicado: (2022) -
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
por: Straatmijer, Tessa, et al.
Publicado: (2023)